The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan

References

• National Cancer Institute: Surveillance, E., and End Results Program. Cancer stat facts: female breast cancer subtypes. 2023 [cited 2023 Jun 1]. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html
   Google Scholar
• Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–1366. doi: 10.1200/JCO.19.02309
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond, ME, Allison, KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364–1382. doi: 10.5858/arpa.2018-0902-SA
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. HER2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update summary. J Oncol Pract. 2018;14(7):437–441. doi: 10.1200/JOP.18.00206
   PubMed Web of Science ®Google Scholar
• Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–1962. doi: 10.1200/JCO.19.02488
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer version 4.2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–226. doi: 10.1056/NEJMoa2202809
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi: 10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59. doi: 10.1016/S1470-2045(19)30689-8
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a Germline BRCA mutation. N Engl J Med. 2018;379(8):753–763. doi: 10.1056/NEJMoa1802905
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. doi: 10.1056/NEJMoa1706450
   PubMed Web of Science ®Google Scholar
• Poggio F, Bruzzone M, Ceppi M, et al. Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open. 2018;3(4):e000361. doi: 10.1136/esmoopen-2018-000361
   PubMed Web of Science ®Google Scholar
• Schreiber AR, Andress M, Diamond JR. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Expert Rev Anticancer Ther. 2021;21(12):1303–1311. doi: 10.1080/14737140.2021.1993065
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–1541. doi: 10.1056/NEJMoa2028485
   PubMed Web of Science ®Google Scholar
• FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. 2021 [cited 2021 Aug, 3]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer
   Google Scholar
• Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254–e262. doi: 10.1016/S1470-2045(16)30030-4
   PubMed Web of Science ®Google Scholar
• Chia CSB. A patent review on FDA-Approved antibody-drug conjugates, their linkers and drug payloads. ChemMedchem. 2022;17(11):e202200032. doi: 10.1002/cmdc.202200032
   PubMed Web of Science ®Google Scholar
• Shastry M, Jacob S, Rugo HS. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169–177. doi: 10.1016/j.breast.2022.10.007
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–5108. doi: 10.1158/1078-0432.CCR-15-2822
   PubMed Web of Science ®Google Scholar
• Yan M, Parker BA, Schwab R, et al. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40(6):770–780. doi: 10.1016/j.ctrv.2014.02.008
   PubMed Web of Science ®Google Scholar
• Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34(1):157–164. doi: 10.1007/s10555-015-9552-6
   PubMed Web of Science ®Google Scholar
• Kumazawa E, Jimbo T, Ochi Y, et al. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol. 1998;42(3):210–220. doi: 10.1007/s002800050807
   PubMed Web of Science ®Google Scholar
• Gokduman K. Strategies targeting DNA topoisomerase I in cancer chemotherapy: camptothecins, Nanocarriers for camptothecins, organic non-camptothecin compounds and metal complexes. Curr Drug Targets. 2016;17(16):1928–1939. doi: 10.2174/1389450117666160502151707
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–1046. doi: 10.1111/cas.12966
   PubMed Web of Science ®Google Scholar
• Giugliano F, Corti C, Tarantino P, et al. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24(7):809–817. doi: 10.1007/s11912-022-01266-4
   PubMed Web of Science ®Google Scholar
• Nagai Y, Oitate M, Shiozawa H, et al. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Xenobiotica. 2019;49(9):1086–1096. doi: 10.1080/00498254.2018.1531158
   PubMed Web of Science ®Google Scholar
• Okamoto H, Oitate M, Hagihara K, et al. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica. 2020;50(10):1242–1250. doi: 10.1080/00498254.2020.1755909
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–1522. doi: 10.1016/S1470-2045(17)30604-6
   PubMed Web of Science ®Google Scholar
• Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816–826. doi: 10.1016/S1470-2045(19)30097-X
   PubMed Web of Science ®Google Scholar
• Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a Phase ib study. J Clin Oncol. 2020;38(17):1887–1896. doi: 10.1200/JCO.19.02318
   PubMed Web of Science ®Google Scholar
• Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5(7):953–962.
   PubMed Web of Science ®Google Scholar
• Diéras V, Deluche E, Lusque A, et al. Abstract PD8-02: trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY). Cancer Res. 2022;82(4_Supplement):PD8-02-PD8–02. doi: 10.1158/1538-7445.SABCS21-PD8-02
   Web of Science ®Google Scholar
• Tarantino P, Curigliano G, Tolaney SM. Navigating the HER2-low paradigm in breast oncology: new standards, future horizons. Cancer Discov. 2022;12(9):2026–2030. doi: 10.1158/2159-8290.CD-22-0703
   PubMed Web of Science ®Google Scholar
• Epaillard NALAAPBAAFABTAPJ-YADAAJCAVFAS, Lusque A, Pistilli B. 260P antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial. Ann Oncol. 2022;33:S656. doi: 10.1016/j.annonc.2022.07.299
   Web of Science ®Google Scholar
• Jerusalem G, Park YH, Yamashita T et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis. Cancer Discov. 2022;12(12):2754–2762. doi: 10.1158/2159-8290.CD-22-0837
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in Previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol. 2020;38(5):444–453. doi: 10.1200/JCO.19.01455
   PubMed Web of Science ®Google Scholar
• Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405. doi: 10.1200/JCO.2010.29.5865
   PubMed Web of Science ®Google Scholar
• Nicolò E, Boscolo Bielo L, Curigliano G, et al. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol. 2023;15:17588359231152842. doi: 10.1177/17588359231152842
   Web of Science ®Google Scholar
• Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–1135. doi: 10.1016/S1470-2045(19)30328-6
   PubMed Web of Science ®Google Scholar
• Wang J, Liu Y, Zhang Q, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. J Clin Oncol. 2021;39(15_suppl):1022–1022. doi: 10.1200/JCO.2021.39.15_suppl.1022
   Web of Science ®Google Scholar
• Jiang Z, Sun T, Wang X, et al. A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer. J Clin Oncol. 2022;40(16_suppl):1102–1102. doi: 10.1200/JCO.2022.40.16_suppl.1102
   PubMed Web of Science ®Google Scholar
• Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101–126. doi: 10.1038/s41573-022-00579-0
   PubMed Web of Science ®Google Scholar
• Skidmore L, Sakamuri S, Knudsen NA, et al. ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers. Mol Cancer Ther. 2020;19(9):1833–1843. doi: 10.1158/1535-7163.MCT-19-1004
   PubMed Web of Science ®Google Scholar
• Colombo R, Rich JR. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell. 2022;40(11):1255–1263. doi: 10.1016/j.ccell.2022.09.016
   PubMed Web of Science ®Google Scholar
• Prat A, Bardia A, Curigliano G, et al. An overview of clinical development of agents for metastatic or advanced breast cancer without ERBB2 amplification (HER2-low). JAMA Oncol. 2022;8(11): doi: 10.1001/jamaoncol.2022.4175
   PubMed Web of Science ®Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566. doi: 10.1093/annonc/mdz012
   PubMed Web of Science ®Google Scholar
• Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32(9):1148–1156. doi: 10.1016/j.annonc.2021.06.002
   PubMed Web of Science ®Google Scholar
• Weiss J, Glode A, Messersmith WA, et al. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. Expert Rev Anticancer Ther. 2019;19(8):673–679. doi: 10.1080/14737140.2019.1654378
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology-college of American pathologists guideline update. Arch Pathol Lab Med. 2023;147(9):993–1000. doi: 10.5858/arpa.2023-0950-SA
   PubMedGoogle Scholar
• Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1. doi: 10.1038/s41523-020-00208-2
   PubMed Web of Science ®Google Scholar
• Hamilton E, Shastry M, Shiller SM, et al. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:102286. doi: 10.1016/j.ctrv.2021.102286
   PubMed Web of Science ®Google Scholar
• Pérez-García JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023;25(1):157–166. doi: 10.1093/neuonc/noac144
   PubMed Web of Science ®Google Scholar
• Krop I, Juric D, Shimizu T, et al. Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study. Cancer Res. 2022;82(4_Supplement):GS1-05-GS1–05. doi: 10.1158/1538-7445.SABCS21-GS1-05
   Web of Science ®Google Scholar